Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM Oncology Drugs

Retrieved on: 2019-04-17 22:26:15

Tags for this article:

Drug discovery

RNA

Biotechnology companies

Arrakis Therapeutics

Druggability

Click the tags to see associated articles and topics

Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM Oncology Drugs. View article details on hiswai:

Excerpt

<div>Financing participants included new investors Omega Funds, HBM Healthcare Investments, GV (formerly <b>Google Ventures</b>), WuXi AppTec Venture ...</div>

Article found on:

View Original Article